Cytek Biosciences Inc. (CTKB)
CTKB trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/0001628280-26-012352-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CTKB on Nasdaq |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001831915 |
| SEC industry code | Laboratory Analytical Instruments |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $201.5M |
| Net income | -$66.5M |
| Operating income | -$40.4M |
| Net margin | -33.0% |
| Operating margin | -20.0% |
| Revenue growth | +0.5% |
| Cash | $90.9M |
| Total assets | $461.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $66.8M cash; operating cash flow -$1.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 130,783,967 (2026-10-31); 127,864,830 a year earlier; 135,549,154 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Jose, California, United States | PCAOB Form AP 2026-03-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $53.2M | -$6.1M | -$4.5M | $66.8M | No debt tags | $207.6M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $48.1M | -$12.2M | $1.4M | $73.8M | No debt tags | $206.7M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $44.1M | -$18.9M | -$2.7M | $65.7M | No debt tags | $204.2M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $62.1M | -$44.1M | -$771K | $90.9M | No debt tags | $201.5M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $52.3M | -$5.5M | -$3.9M | $93.3M | No debt tags | $196.8M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $45.6M | -$5.6M | $108K | $75.5M | No debt tags | $196.0M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $41.5M | -$11.4M | -$125K | $95.3M | No debt tags | $197.1M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $57.5M | $9.6M | $2.0M | $98.7M | No debt tags | $200.5M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2022-08-26 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 466 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.2% |
| 1 month | +9.2% |
| 3 months | +19.4% |
| Year to date | +15.6% |
| 1 year | +27.8% |
| From 52-week high | -7.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PACB | Pacific Biosciences of California Inc. | $1.84 | -6.12% | $575.8M |
| NAUT | Nautilus Biotechnology Inc. | $2.10 | -9.48% | $267.5M |
| ALMR | Alamar Biosciences Inc. | $30.55 | -0.84% | $2.1B |
| LAB | Standard BioTools Inc. | $0.6210 | -12.21% | $245.2M |
| QTRX | Quanterix Corporation | $2.84 | -3.07% | $134.8M |
| SEER | Seer Inc. | $1.48 | -5.73% | $82.6M |
| TXG | 10x Genomics Inc. | $54.99 | -5.50% | $7.2B |
| BRKR | Bruker Corporation | $60.62 | -1.57% | $9.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier